CA2084888A1 - Intercellular adhesion mediators - Google Patents

Intercellular adhesion mediators

Info

Publication number
CA2084888A1
CA2084888A1 CA002084888A CA2084888A CA2084888A1 CA 2084888 A1 CA2084888 A1 CA 2084888A1 CA 002084888 A CA002084888 A CA 002084888A CA 2084888 A CA2084888 A CA 2084888A CA 2084888 A1 CA2084888 A1 CA 2084888A1
Authority
CA
Canada
Prior art keywords
alpha
beta
composition
3gal
selectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002084888A
Other languages
English (en)
French (fr)
Inventor
James C. Paulson
Mary S. Perez
Federico C. A. Gaeta
Robert Murray Ratcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytel Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2084888A1 publication Critical patent/CA2084888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002084888A 1990-06-15 1991-06-14 Intercellular adhesion mediators Abandoned CA2084888A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US53885390A 1990-06-15 1990-06-15
US538,853 1990-06-15
US61931990A 1990-11-28 1990-11-28
US619,319 1990-11-28
US63239090A 1990-12-21 1990-12-21
US632,390 1990-12-21
WOPCT/US91/03592 1991-05-22
PCT/US1991/003592 WO1991019501A1 (en) 1990-06-15 1991-05-22 Intercellular adhesion mediators

Publications (1)

Publication Number Publication Date
CA2084888A1 true CA2084888A1 (en) 1991-12-16

Family

ID=27415280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002084888A Abandoned CA2084888A1 (en) 1990-06-15 1991-06-14 Intercellular adhesion mediators

Country Status (12)

Country Link
EP (1) EP0533834A1 (enrdf_load_stackoverflow)
AU (2) AU8007791A (enrdf_load_stackoverflow)
BR (1) BR9106556A (enrdf_load_stackoverflow)
CA (1) CA2084888A1 (enrdf_load_stackoverflow)
FI (1) FI925668A0 (enrdf_load_stackoverflow)
HU (1) HU216312B (enrdf_load_stackoverflow)
IE (1) IE912048A1 (enrdf_load_stackoverflow)
IL (1) IL98493A (enrdf_load_stackoverflow)
NO (1) NO924830L (enrdf_load_stackoverflow)
NZ (1) NZ238556A (enrdf_load_stackoverflow)
SG (1) SG52563A1 (enrdf_load_stackoverflow)
WO (2) WO1991019501A1 (enrdf_load_stackoverflow)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) * 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US5648344A (en) * 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
CA2108786A1 (en) * 1991-04-19 1992-10-20 John L. Magnani Compositions and methods for endothelial binding
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
CA2110495A1 (en) * 1991-06-10 1992-12-23 Robert M. Ippolito Immunosuppressive and tolerogenic oligosaccharide derivatives
GB9114657D0 (en) * 1991-07-06 1991-08-21 Antisoma Ltd Diagnostic compounds
WO1993005803A1 (en) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Anti-inflammatory selectin inhibitors
ES2140419T3 (es) * 1991-10-31 2000-03-01 Fujisawa Pharmaceutical Co Preparacion de liposoma que contiene un compuesto triciclico.
GB9208339D0 (en) * 1992-04-15 1992-06-03 Unilever Plc Treatment composition
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
WO1993024527A1 (en) * 1992-05-28 1993-12-09 Centocor, Inc. Peptide inhibitors of selectin binding
CA2136844A1 (en) * 1992-05-28 1993-12-09 George A. Heavner Peptide inhibitors of selectin binding
CA2100412A1 (en) * 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
WO1994002178A1 (en) * 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
WO1994005310A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of cellular adhesion
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994007517A1 (en) 1992-10-02 1994-04-14 Alberta Research Council Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US6406894B1 (en) 1992-12-11 2002-06-18 Glycorex Ab Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
AU6353294A (en) * 1993-03-01 1994-09-26 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
US5763413A (en) * 1993-03-04 1998-06-09 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
US5854218A (en) * 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5811404A (en) * 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
ATE215094T1 (de) 1993-05-17 2002-04-15 Avant Immunotherapeutics Inc Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) * 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
AU1255695A (en) * 1993-11-19 1995-06-06 Regents Of The University Of California, The Sulfated ligands for l-selectin and methods of preventing sulfate addition
US5783693A (en) * 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
DE4431280A1 (de) 1994-09-02 1996-03-07 Hoechst Ag Verfahren zur Isolierung und Reinigung von nukleotidaktivierten Zuckern aus biologischen Quellen
EP0783508A1 (en) * 1994-09-20 1997-07-16 PHARMACIA & UPJOHN COMPANY The oligosaccharide structure of a ligand for e and p selectin
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5599915A (en) * 1995-03-21 1997-02-04 The Scripps Research Institute Sialyl Lewis X mimetics
EP1428832A3 (en) * 1995-08-03 2004-09-22 The Board of Regents for the University of Oklahoma Peptide and O-glycan inhibitors of selectin mediated inflammation
US5876715A (en) * 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
EP0765884B1 (en) * 1995-08-17 2004-04-14 The Biomembrane Institute Anti-inflammatory compound
US5965544A (en) * 1995-09-29 1999-10-12 Glycim Oy Synthetic multivalent sLex containing polylactosamines and methods for use
AU7445796A (en) * 1995-10-18 1997-05-07 Cytel Corporation Sialyl lex analogues as inhibitors of cellular adhesion
WO1997018222A2 (en) * 1995-11-13 1997-05-22 Glycomed, Inc. Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties
JP2001516334A (ja) * 1996-03-01 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア セレクチン結合の阻害
US6033663A (en) * 1996-04-10 2000-03-07 Neose Technologies, Inc. Nucleic acids encoding GDP-Fucose pyrophosphorylase
US5830871A (en) * 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
EP0834572A3 (en) * 1996-10-02 1999-08-25 F. Hoffmann-La Roche Ag Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives
EP1015464A2 (en) 1997-09-05 2000-07-05 Glycim Oy SYNTHETIC DIVALENT sLex CONTAINING POLYLACTOSAMINES AND METHODS FOR USE
DK2270150T4 (da) * 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7127357B1 (en) 2000-12-08 2006-10-24 The Salk Institute For Biological Studies Crystal structure of WW domains and methods of use thereof
KR20040015234A (ko) 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
WO2002089819A1 (en) * 2001-05-07 2002-11-14 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Glycoconjugates and uses thereof
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
ATE412897T1 (de) 2003-05-30 2008-11-15 Purdue Research Foundation Diagnoseverfahren für atherosklerose
EP1655022A4 (en) * 2003-08-01 2010-04-07 Nat Inst Of Advanced Ind Scien MEANS FOR THE TREATMENT OR DIAGNOSIS OF INFLAMMATORY DISEASES WITH A TARGETED LIPOSOM
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
DE602004011272T2 (de) 2003-11-19 2008-12-24 Glycomimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
AU2006280101B2 (en) 2005-08-09 2012-06-28 Glycomimetics, Inc. Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
ES2651929T3 (es) 2005-09-02 2018-01-30 Glycomimetics, Inc. Inhibidores de pan-selectina heterobifuncionales
EP1940473A2 (en) 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2008057437A2 (en) 2006-11-03 2008-05-15 Purdue Research Foundation Ex vivo flow cytometry method and device
JP5869205B2 (ja) 2007-02-07 2016-02-24 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ポジトロン放射断層画像法
CA2688308A1 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
BRPI0924078A2 (pt) 2009-01-22 2018-10-16 Momenta Pharmaceuticals Inc n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho.
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
JP2015500887A (ja) 2011-12-22 2015-01-08 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物、組成物および使用方法
PL2928476T3 (pl) 2012-12-07 2018-07-31 Glycomimetics, Inc. Związki, kompozycje i sposoby wykorzystujące antagonistów e-selektyny do mobilizacji komórek hematopoietycznych
AU2015355136B2 (en) 2014-12-03 2020-06-25 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
BR112020013198A2 (pt) 2017-12-29 2020-12-01 Glycomimetics, Inc. inibidores heterobifuncionais de e-selectina e galectina-3
JP7455064B2 (ja) 2018-03-05 2024-03-25 グリコミメティクス， インコーポレイテッド 急性骨髄性白血病および関連状態を処置する方法
CN110317274A (zh) * 2018-03-30 2019-10-11 积水医疗株式会社 与ncc-st-439抗原特异性反应的单克隆抗体及其制造方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2721900B2 (ja) * 1988-09-18 1998-03-04 株式会社ニチレイ 癌診断薬及びそれを用いた腫瘍マーカーの回収方法
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells

Also Published As

Publication number Publication date
AU660931B2 (en) 1995-07-13
FI925668A7 (fi) 1992-12-14
EP0533834A4 (enrdf_load_stackoverflow) 1995-04-19
IL98493A (en) 1998-12-06
NO924830L (no) 1993-02-08
BR9106556A (pt) 1991-12-26
HU9204091D0 (en) 1993-11-29
HU216312B (hu) 1999-06-28
SG52563A1 (en) 1998-09-28
NZ238556A (en) 1994-01-26
AU8102991A (en) 1992-01-07
AU8007791A (en) 1992-01-07
WO1991019501A1 (en) 1991-12-26
FI925668L (fi) 1992-12-14
WO1991019502A1 (en) 1991-12-26
NO924830D0 (no) 1992-12-14
FI925668A0 (fi) 1992-12-14
EP0533834A1 (en) 1993-03-31
IE912048A1 (en) 1991-12-18
HUT69652A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
AU660931B2 (en) Intercellular adhesion mediators
US5753631A (en) Intercellular adhesion mediators
US5576305A (en) Intercellular adhesion mediators
EP0730608B1 (en) Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5559103A (en) Bivalent sialyl X saccharides
US5976540A (en) Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
AU658383B2 (en) Agents and methods for binding to elam-1
RU2123338C1 (ru) Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
Aigner et al. Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin
Nelson et al. Higher-affinity oligosaccharide ligands for E-selectin.
US5856300A (en) Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5604207A (en) Sialyl Lex analogues as inhibitors of cellular adhesion
CA2109212A1 (en) Assays for inhibitors of leukocyte adhesion
JPH11147900A (ja) Ｇｍｐ−１４０に特異的な結合を有する糖タンパク質リガンドに対する抗体
WO1992016612A2 (en) Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component
Parekh et al. Selectins-glycoprotein targets for therapeutic intervention in inflammation
Unger The chemistry of oligosaccharide ligands of selectins: significance for the development of new immunomodulatory medicines
WO1995021618A1 (en) Immunomodulation using nkr-p1, cd69 and ligands therefor
US5972625A (en) Assays for inhibitors of leukocyte adhesion
US5807745A (en) Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
JPH05507519A (ja) 細胞間付着仲介因子
JPH05507923A (ja) 細胞間付着仲介因子
AU678486C (en) Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
NZ299428A (en) Liposome with sialyl lewis x determinant on its surface that binds elam-1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued